RUNX1 and acute myeloid leukemia: In about 20% of patients with AML, excluding acute promyelocytic leukemia (APL), distinct fusion genes are approachable for MRD monitoring with most of them represented by core-binding factor (CBF) AML (RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes) [1,12,13,59].